Ophthalmology Disorders Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Publish Date : 2021-03-14 | Publisher : 99Strategy | No Of Page : 191 | Report Id : MRB000119033 |

   

Report

MRB

Ophthalmology Disorders Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Publish Date: 2021-03-14 No Of Page: 191 Report Id: MRB000119033 Publisher: 99Strategy Category: Medical Care

Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.

The global Ophthalmology Disorders Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Ophthalmology Disorders Drug market segmented into
Oral
Injection
External Use

Based on the end-use, the global Ophthalmology Disorders Drug market classified into
Juvenile Macular Degeneration (Stargardt Disease)
Leber Congenital Amaurosis (LCA)
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
Usher Syndrome
Retinitis Pigmentosa (Retinitis)

Based on geography, the global Ophthalmology Disorders Drug market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are
Sanofi
Bayer
Bausch + Lomb
Novartis
Usher Syndrome
Takeda Pharmaceutical
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
ReNeuron
Amarantus BioScience
Ocugen
ReGenX Biosciences
Sucampo Pharmaceuticals
Orphagen Pharmaceuticals
Okuvision
Second Sight Medical
Acucela
Stealth BioTherapeutics
Sun Pharma Advanced Research Company
AmpliPhi Biosciences
Applied Genetic Technologies
Asklepios BioPharmaceutical
Biovista
Spark Therapeutics
Caladrius Biosciences
Dompe Farmaceutici
Dormant Projects
Grupo Ferrer Internacional
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Ixchel Pharma
Khondrion
Mimetogen Pharmaceuticals
Mitotech
M's Science
Nanovector
SanBio

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL OPHTHALMOLOGY DISORDERS DRUG INDUSTRY
2.1 Summary about Ophthalmology Disorders Drug Industry
2.2 Ophthalmology Disorders Drug Market Trends
2.2.1 Ophthalmology Disorders Drug Production & Consumption Trends
2.2.2 Ophthalmology Disorders Drug Demand Structure Trends
2.3 Ophthalmology Disorders Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Oral
4.2.2 Injection
4.2.3 External Use
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Juvenile Macular Degeneration (Stargardt Disease)
4.3.2 Leber Congenital Amaurosis (LCA)
4.3.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
4.3.4 Usher Syndrome
4.3.5 Retinitis Pigmentosa (Retinitis)
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Oral
5.2.2 Injection
5.2.3 External Use
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Juvenile Macular Degeneration (Stargardt Disease)
5.3.2 Leber Congenital Amaurosis (LCA)
5.3.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
5.3.4 Usher Syndrome
5.3.5 Retinitis Pigmentosa (Retinitis)
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Oral
6.2.2 Injection
6.2.3 External Use
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Juvenile Macular Degeneration (Stargardt Disease)
6.3.2 Leber Congenital Amaurosis (LCA)
6.3.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
6.3.4 Usher Syndrome
6.3.5 Retinitis Pigmentosa (Retinitis)
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Oral
7.2.2 Injection
7.2.3 External Use
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Juvenile Macular Degeneration (Stargardt Disease)
7.3.2 Leber Congenital Amaurosis (LCA)
7.3.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
7.3.4 Usher Syndrome
7.3.5 Retinitis Pigmentosa (Retinitis)
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Oral
8.2.2 Injection
8.2.3 External Use
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Juvenile Macular Degeneration (Stargardt Disease)
8.3.2 Leber Congenital Amaurosis (LCA)
8.3.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
8.3.4 Usher Syndrome
8.3.5 Retinitis Pigmentosa (Retinitis)
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Oral
9.2.2 Injection
9.2.3 External Use
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Juvenile Macular Degeneration (Stargardt Disease)
9.3.2 Leber Congenital Amaurosis (LCA)
9.3.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
9.3.4 Usher Syndrome
9.3.5 Retinitis Pigmentosa (Retinitis)
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sanofi
10.1.2 Bayer
10.1.3 Bausch + Lomb
10.1.4 Novartis
10.1.5 Usher Syndrome
10.1.6 Takeda Pharmaceutical
10.1.7 Roche
10.1.8 Pfizer
10.1.9 Allergan
10.1.10 Gilead Sciences
10.1.11 Kubota Pharmaceutical
10.1.12 Alkeus Pharmaceuticals
10.1.13 Astellas Pharma
10.1.14 Ferrer Corporate
10.1.15 Amgen Inc
10.1.16 Editas Medicine Inc
10.1.17 ProQR Therapeutics NV
10.1.18 ReNeuron
10.1.19 Amarantus BioScience
10.1.20 Ocugen
10.1.21 ReGenX Biosciences
10.1.22 Sucampo Pharmaceuticals
10.1.23 Orphagen Pharmaceuticals
10.1.24 Okuvision
10.1.25 Second Sight Medical
10.1.26 Acucela
10.1.27 Stealth BioTherapeutics
10.1.28 Sun Pharma Advanced Research Company
10.1.29 AmpliPhi Biosciences
10.1.30 Applied Genetic Technologies
10.1.31 Asklepios BioPharmaceutical
10.1.32 Biovista
10.1.33 Spark Therapeutics
10.1.34 Caladrius Biosciences
10.1.35 Dompe Farmaceutici
10.1.36 Dormant Projects
10.1.37 Grupo Ferrer Internacional
10.1.38 ID Pharma
10.1.39 InFlectis BioScience
10.1.40 Ionis Pharmaceuticals
10.1.41 Ixchel Pharma
10.1.42 Khondrion
10.1.43 Mimetogen Pharmaceuticals
10.1.44 Mitotech
10.1.45 M's Science
10.1.46 Nanovector
10.1.47 SanBio
10.2 Ophthalmology Disorders Drug Sales Date of Major Players (2017-2020e)
10.2.1 Sanofi
10.2.2 Bayer
10.2.3 Bausch + Lomb
10.2.4 Novartis
10.2.5 Usher Syndrome
10.2.6 Takeda Pharmaceutical
10.2.7 Roche
10.2.8 Pfizer
10.2.9 Allergan
10.2.10 Gilead Sciences
10.2.11 Kubota Pharmaceutical
10.2.12 Alkeus Pharmaceuticals
10.2.13 Astellas Pharma
10.2.14 Ferrer Corporate
10.2.15 Amgen Inc
10.2.16 Editas Medicine Inc
10.2.17 ProQR Therapeutics NV
10.2.18 ReNeuron
10.2.19 Amarantus BioScience
10.2.20 Ocugen
10.2.21 ReGenX Biosciences
10.2.22 Sucampo Pharmaceuticals
10.2.23 Orphagen Pharmaceuticals
10.2.24 Okuvision
10.2.25 Second Sight Medical
10.2.26 Acucela
10.2.27 Stealth BioTherapeutics
10.2.28 Sun Pharma Advanced Research Company
10.2.29 AmpliPhi Biosciences
10.2.30 Applied Genetic Technologies
10.2.31 Asklepios BioPharmaceutical
10.2.32 Biovista
10.2.33 Spark Therapeutics
10.2.34 Caladrius Biosciences
10.2.35 Dompe Farmaceutici
10.2.36 Dormant Projects
10.2.37 Grupo Ferrer Internacional
10.2.38 ID Pharma
10.2.39 InFlectis BioScience
10.2.40 Ionis Pharmaceuticals
10.2.41 Ixchel Pharma
10.2.42 Khondrion
10.2.43 Mimetogen Pharmaceuticals
10.2.44 Mitotech
10.2.45 M's Science
10.2.46 Nanovector
10.2.47 SanBio
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Table
1.Table Ophthalmology Disorders Drug Product Type Overview
2.Table Ophthalmology Disorders Drug Product Type Market Share List
3.Table Ophthalmology Disorders Drug Product Type of Major Players
4.Table Brief Introduction of Sanofi
5.Table Brief Introduction of Bayer
6.Table Brief Introduction of Bausch + Lomb
7.Table Brief Introduction of Novartis
8.Table Brief Introduction of Usher Syndrome
9.Table Brief Introduction of Takeda Pharmaceutical
10.Table Brief Introduction of Roche
11.Table Brief Introduction of Pfizer
12.Table Brief Introduction of Allergan
13.Table Brief Introduction of Gilead Sciences
14.Table Brief Introduction of Kubota Pharmaceutical
15.Table Brief Introduction of Alkeus Pharmaceuticals
16.Table Brief Introduction of Astellas Pharma
17.Table Brief Introduction of Ferrer Corporate
18.Table Brief Introduction of Amgen Inc
19.Table Brief Introduction of Editas Medicine Inc
20.Table Brief Introduction of ProQR Therapeutics NV
21.Table Brief Introduction of ReNeuron
22.Table Brief Introduction of Amarantus BioScience
23.Table Brief Introduction of Ocugen
24.Table Brief Introduction of ReGenX Biosciences
25.Table Brief Introduction of Sucampo Pharmaceuticals
26.Table Brief Introduction of Orphagen Pharmaceuticals
27.Table Brief Introduction of Okuvision
28.Table Brief Introduction of Second Sight Medical
29.Table Brief Introduction of Acucela
30.Table Brief Introduction of Stealth BioTherapeutics
31.Table Brief Introduction of Sun Pharma Advanced Research Company
32.Table Brief Introduction of AmpliPhi Biosciences
33.Table Brief Introduction of Applied Genetic Technologies
34.Table Brief Introduction of Asklepios BioPharmaceutical
35.Table Brief Introduction of Biovista
36.Table Brief Introduction of Spark Therapeutics
37.Table Brief Introduction of Caladrius Biosciences
38.Table Brief Introduction of Dompe Farmaceutici
39.Table Brief Introduction of Dormant Projects
40.Table Brief Introduction of Grupo Ferrer Internacional
41.Table Brief Introduction of ID Pharma
42.Table Brief Introduction of InFlectis BioScience
43.Table Brief Introduction of Ionis Pharmaceuticals
44.Table Brief Introduction of Ixchel Pharma
45.Table Brief Introduction of Khondrion
46.Table Brief Introduction of Mimetogen Pharmaceuticals
47.Table Brief Introduction of Mitotech
48.Table Brief Introduction of M's Science
49.Table Brief Introduction of Nanovector
50.Table Brief Introduction of SanBio
51.Table Products & Services of Sanofi
52.Table Products & Services of Bayer
53.Table Products & Services of Bausch + Lomb
54.Table Products & Services of Novartis
55.Table Products & Services of Usher Syndrome
56.Table Products & Services of Takeda Pharmaceutical
57.Table Products & Services of Roche
58.Table Products & Services of Pfizer
59.Table Products & Services of Allergan
60.Table Products & Services of Gilead Sciences
61.Table Products & Services of Kubota Pharmaceutical
62.Table Products & Services of Alkeus Pharmaceuticals
63.Table Products & Services of Astellas Pharma
64.Table Products & Services of Ferrer Corporate
65.Table Products & Services of Amgen Inc
66.Table Products & Services of Editas Medicine Inc
67.Table Products & Services of ProQR Therapeutics NV
68.Table Products & Services of ReNeuron
69.Table Products & Services of Amarantus BioScience
70.Table Products & Services of Ocugen
71.Table Products & Services of ReGenX Biosciences
72.Table Products & Services of Sucampo Pharmaceuticals
73.Table Products & Services of Orphagen Pharmaceuticals
74.Table Products & Services of Okuvision
75.Table Products & Services of Second Sight Medical
76.Table Products & Services of Acucela
77.Table Products & Services of Stealth BioTherapeutics
78.Table Products & Services of Sun Pharma Advanced Research Company
79.Table Products & Services of AmpliPhi Biosciences
80.Table Products & Services of Applied Genetic Technologies
81.Table Products & Services of Asklepios BioPharmaceutical
82.Table Products & Services of Biovista
83.Table Products & Services of Spark Therapeutics
84.Table Products & Services of Caladrius Biosciences
85.Table Products & Services of Dompe Farmaceutici
86.Table Products & Services of Dormant Projects
87.Table Products & Services of Grupo Ferrer Internacional
88.Table Products & Services of ID Pharma
89.Table Products & Services of InFlectis BioScience
90.Table Products & Services of Ionis Pharmaceuticals
91.Table Products & Services of Ixchel Pharma
92.Table Products & Services of Khondrion
93.Table Products & Services of Mimetogen Pharmaceuticals
94.Table Products & Services of Mitotech
95.Table Products & Services of M's Science
96.Table Products & Services of Nanovector
97.Table Products & Services of SanBio
98.Table Market Distribution of Major Players
99.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
100.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
101.Table Global Ophthalmology Disorders Drug Market Forecast (Million USD) by Region 2021f-2026f
102.Table Global Ophthalmology Disorders Drug Market Forecast (Million USD) Share by Region 2021f-2026f
103.Table Global Ophthalmology Disorders Drug Market Forecast (Million USD) by Demand 2021f-2026f
104.Table Global Ophthalmology Disorders Drug Market Forecast (Million USD) Share by Demand 2021f-2026f

Neurologic Disorders Therapeutics Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Summary Further key aspects of the report indicate that: Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology Chapter 2: Global Industry Summary Chapter 3: Market Dynamics Chapter 4: Global Market Segme ...
Published Date :  2021-03-14

Thyroid Gland Disorders Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Summary Further key aspects of the report indicate that: Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology Chapter 2: Global Industry Summary Chapter 3: Market Dynamics Chapter 4: Global Market Segme ...
Published Date :  2021-03-14

Substance Use Disorders (SUDs) Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Summary Further key aspects of the report indicate that: Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology Chapter 2: Global Industry Summary Chapter 3: Market Dynamics Chapter 4: Global Market Segme ...
Published Date :  2021-03-14

2015-2025 Global Substance Use Disorders (SUDs) Treatment Market Research by Type, End-Use and Region

Summary The global Substance Use Disorders (SUDs) Treatment market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025. Further key aspects of the report indicate that: Chapter 1: Market D ...
Published Date :  2020-10-20

2015-2025 Global Ophthalmology Disorders Drug Market Research by Type, End-Use and Region (COVID-19 Version)

Summary The global Ophthalmology Disorders Drug market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025. Further key aspects of the report indicate that: Chapter 1: Market Definition an ...
Published Date :  2020-10-20